UK markets closed
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • FTSE 250

    20,961.31
    -334.92 (-1.57%)
     
  • AIM

    1,163.26
    -10.13 (-0.86%)
     
  • GBP/EUR

    1.1598
    +0.0001 (+0.01%)
     
  • GBP/USD

    1.3814
    -0.0080 (-0.58%)
     
  • BTC-GBP

    34,691.10
    -1,544.13 (-4.26%)
     
  • CMC Crypto 200

    958.86
    +15.69 (+1.66%)
     
  • S&P 500

    3,790.05
    +21.58 (+0.57%)
     
  • DOW

    31,133.68
    +209.54 (+0.68%)
     
  • CRUDE OIL

    66.03
    +2.20 (+3.45%)
     
  • GOLD FUTURES

    1,699.30
    -1.40 (-0.08%)
     
  • NIKKEI 225

    28,864.32
    -65.79 (-0.23%)
     
  • HANG SENG

    29,098.29
    -138.50 (-0.47%)
     
  • DAX

    13,920.69
    -135.65 (-0.97%)
     
  • CAC 40

    5,782.65
    -48.00 (-0.82%)
     

Biotest AG: Biotest significantly exceeds Revenue and EBIT guidance

·4-min read

Biotest AG / Key word(s): Preliminary Results
Biotest AG: Biotest significantly exceeds Revenue and EBIT guidance

11-Feb-2021 / 17:54 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Ad-hoc RELEASE
Announcement according to Article 17 European Market Abuse Regulation (MAR)

Biotest significantly exceeds Revenue and EBIT guidance

Dreieich, 11 February 2021. According to preliminary and not yet audited figures, Biotest AG increased its revenues by more than 15% to € 484 million in fiscal year 2020, compared to € 419 million in the previous year. The increase in revenues primarily resulted from higher sales in the regions Middle East and Africa and Rest of Europe. Among other things, the entry into the Chinese market had a positive impact.

Although the year-end closing work is still ongoing, it is becoming apparent that the operating result (earnings before interest and taxes, EBIT) in fiscal 2020 will be between € - 1 to - 2 million. In 2019, EBIT amounted to € - 1.2 million.

Thus Biotest Group concluded 2020 with a significantly better result than what has been published as EBIT guidance of € - 10 million for 2020. The improvement is mainly attributable to higher sales, lower administrative expenses and one-time other operating income in the fourth quarter.

In the 2020 financial year, EBIT continued to be impacted by higher expenses in connection with the start-up phase of the new Biotest Next Level production facility. In addition, higher research and development expenses for the new products, which will be manufactured exclusively in the Biotest Next Level facility, as well as two additionally, initiated development projects for a therapy against a COVID-19 infection negatively influenced the result.

Biotest will publish final results for the Financial Year 2020 and the annual report on March 31, 2021. The virtual Annual General Meeting of Biotest AG without physical presence will take place on May 11, 2021.


Biotest Aktiengesellschaft
Board of Management

Biotest AG
Landsteinerstr. 5
D-63303 Dreieich
www.biotest.com

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 1,900 employees worldwide. The preference shares of Biotest AG are listed in the Prime Standard on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate




Contact:
Dr. Michael Ramroth
Chief Financial Officer
Biotest AG
Landsteinerstr. 3
63303 Dreieich
Tel. +40 6103 801 338
Fax: +49 6103 801 347
Michael.ramroth@biotest.com

11-Feb-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Biotest AG

Landsteinerstraße 5

63303 Dreieich

Germany

Phone:

0 61 03 - 8 01-0

Fax:

0 61 03 - 8 01-150

E-mail:

investor_relations@biotest.de

Internet:

http://www.biotest.de

ISIN:

DE0005227235, DE0005227201

WKN:

522723, 522720

Listed:

Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

EQS News ID:

1167844


 

End of Announcement

DGAP News Service

show this
show this